Welcome to our Investor Centre

Please click on the Profiles below to see more details on our other clients:

All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.

ProBiotix Health plc

Company Profile

Company website
Pharmaceuticals and Biotechnology (Biotechnology)

Description: ProBiotix Health (AQSE: PBX) is a spin-out of OptiBiotix Health Plc. The Company was established in 2018, with the purpose to provide consumers and industry world-wide with uncompromised supply and service of safe and scientifically validated probiotic-based microbiome product solutions for improvement of human health.

ProBiotix Health hold a unique position within fast growing cardiovascular health segment and has become a global leader for development and marketing of finished dietary supplement and OTC probiotic based microbiome solution aiming at lowering of cholesterol and blood pressure using its principal strain, LPLDL®.

Investor Access

28 Jun
Event information
The company will release to the Full Year Results (the period ended 31 December 2022) on Wednesday, 28 June 2023
Wednesday, 28 June 2023
Financial Calendar
 Event Date
Year End31 December
Half  Year End30 June
Preliminary Results*June
Interim Results*September

* Months based on previous announcements of this kind